Cencora, Inc. · NYSE:COR
Cencora — Q2 2025 Earnings Presentation
18 slides from Cencora's earnings presentation, May 7, 2025
Slide 1: Second Quarter Fiscal 2025 Earnings Call
Cencora, Inc. Second Quarter Fiscal 2025 Earnings Call May 7, 2025
Slide 2: Cautionary Note Regarding Forward Looking Statements
Cautionary Note Regarding Forward Looking Statements Certain of the statements contained in this presentation are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securit
Slide 3: Creating differentiated value for our stakeholders
Creating differentiated value for our stakeholders Advance core Enhance capabilities business and growth Why we exist We are united in our responsibility • Lead with Invest in • Expand on leadership in to create healthier futures market leaders innovation to Specialty further drive • Leverage infras
Slide 4: Second quarter highlights & strategic overview
Second quarter highlights & strategic overview Company highlights Financial highlights & fiscal 2025 guidance • Cencora released its 2024 Corporate Responsibility Report • Adjusted diluted EPS(1) increased 16.3% year-over-year to $4.42. and microsite, outlining the integration with business objectiv
Slide 5: Financial results
cencora Financial results SS
Slide 6: Q2 fiscal 2025 financial summary
Q2 fiscal 2025 Consolidated results GAAP Adjusted (non-GAAP)(1) financial summary Revenue y/y% $75.5B 10.3% $75.5B 10.3% 10.3% Gross profit $3.1B $2.9B Revenue growth y/y y/y% 20.6% 15.2% 15.3% Operating expenses $2.0B $1.7B Consolidated y/y% 2.0% 15.2% adjusted operating income(1) growth y/y Operat
Slide 7: U.S. Healthcare Solutions segment
U.S. Healthcare Solutions segment Q2 fiscal 2025 financial results Q2 Q2 Financial results y/y% fiscal 2025 fiscal 2024 • Revenue increased 11.4% to $68.3 billion Revenue $68.3B $61.3B 11.4% due to overall market growth primarily driven by unit volume growth, including increased $1.0B $0.8B 22.8% sa
Slide 8: International Healthcare Solutions segment
International Healthcare Solutions segment Q2 fiscal 2025 financial results Constant Financial results Q2 Q2 y/y% currency(1) (as reported) fiscal 2025 fiscal 2024 • Revenue of $7.2 billion was up 0.7% on an y/y% as reported basis. On a constant currency basis, revenue increased by 5.7%. Revenue $7.
Slide 9: Fiscal 2025 guidance
cencora Fiscal 2025 guidance SS
Slide 10: Fiscal 2025 guidance
Fiscal 2025 guidance As reported Constant currency(1) Consolidated Revenue 8% to 10% Adjusted operating income(1)(2) 13.5% to 15.5% U.S. Healthcare Solutions Revenue 9% to 11% Operating income 17.5% to 19.5% International Healthcare Solutions Revenue 3% to 4% 6% to 8% Operating income -4% to -1% -3%
Slide 11: Fiscal 2025 guidance continued
Fiscal 2025 guidance continued Fiscal 2025 Guidance Fiscal 2024 Actual Adjusted diluted earnings per share(1) $15.70 to $15.95 $13.76 Net interest expense $290 to $310 million $157 million Adjusted effective tax rate(1) ~21% 20.8% Diluted weighted average shares outstanding 195.0 to 195.5 million 20
Slide 12: Advancing corporate responsibility initiatives to create healthier futures
Global Corporate Responsibility Building resilient and sustainable operations • Business Resilience: We have performed physical risk assessments using climate models to inform operational planning. • Renewable Energy Initiatives: We continue to explore renewable energy options to enhance sustainabil
Slide 13: Appendix
cencora Appendix
Slide 14: GAAP to Non-GAAP Reconciliations
CENCORA, INC. GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Three Months Ended March 31, 2025 Income Net Income Diluted Operating Operating Before Income Tax Attributable Earnings Gross Profit Expenses Income Income Taxes Expense to Cencora Per Share GAAP $ 3,059
Slide 15: GAAP to Non-GAAP Reconciliations
CENCORA, INC. GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Three Months Ended March 31, 2024 Income Net Income Diluted Operating Operating Before Income Tax Attributable Earnings Gross Profit Expenses Income Income Taxes Expense to Cencora Per Share GAAP $ 2,538
Slide 16: Supplemental information regarding non-GAAP financial measures
Supplemental information regarding non-GAAP financial measures To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses the non-GAAP financial measures described below. The non-GAAP financial measures should be viewed in
Slide 17: Supplemental information regarding non-GAAP financial measures (cont.)
Supplemental information regarding non-GAAP financial measures (cont.) • Adjusted net income attributable to Cencora: Adjusted net income attributable to the Company is a non-GAAP financial measure that excludes the same items that are described above. Management believes that this non- GAAP financi
Slide 18: Contact
Contact Bennett S. Murphy Senior Vice President Head of Investor Relations and Treasury Bennett.Murphy@cencora.com 18